ZFN genome-editing tools were considered worldwide
by many countries to develop new regulations. Argentinian
regulatory framework excludes ZFN-1 from GM regulation,
ZFN-2 would be considered on a case by case basis,
and ZFN-3 will be under product- and process-based regulation.
EU regulatory bodies conclude that ZFN-3 allows
genes of interest to be delivered to predefined genomic
positions, unlike transgenesis, and might be considered
under EU regulations. Australian and New Zealand regulatory
bodies have concluded that ZFN-1 and ZFN-2 would
be excluded but ZFN-3 would be regulated. USA regulatory
bodies consider possible exception of ZFN-1 from regulation
[11]. Other genome-editing tools such as TALENs and
CRISPRs were recently developed and hence regulation
has yet to be defined.